Paradigm Biocapital Advisors portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Paradigm Biocapital Advisors reported a $5.3 bn portfolio of 28 positions to the SEC as of the end of Q2 2026. Its largest positions are RVMD, Nuvalent, EWTX. During the quarter it opened Alnylam Pharmaceuticals and MBX Biosciences and exited Cytokinetics and Abivax.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Paradigm Biocapital Advisors has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
- 13GObsidian Therapeutics6.6 %
Stake reported in the company · event of Sep 28, 2026 · filed Oct 5, 2026 · filing ↗
Stake reported in the company · event of Sep 24, 2026 · filed Oct 1, 2026 · filing ↗
Stake reported in the company · event of Sep 10, 2026 · filed Sep 17, 2026 · filing ↗
Stake reported in the company · event of Jul 10, 2026 · filed Jul 17, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/AAssembly BiosciencesASMB5.4 % → 7.8 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/AArcellxACLX9.9 % → 0 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Plus 2 more, in its EDGAR filings.
What changed this quarter
36 positions with a change (6 new, 12 added to, 7 trimmed, 11 sold); also, 1 entered through an IPO, 3 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Spyre Therapeutics+96%more sharesIncreased2.0% → 6.4%
- Vaxcyte−56%fewer sharesReduced5.7% → 2.3%
- Alnylam Pharmaceuticals+2.7 ppof portfolioNew— → 2.7%
- Genmab A/S+65%more sharesIncreased4.4% → 6.8%
- MBX Biosciences+2.6 ppof portfolioNew— → 2.6%
- Edgewise Therapeutics+39%more sharesIncreased4.7% → 7.8%
- Cytokinetics−1.8 ppof portfolioSold out2.0% → —
- Abivax−1.6 ppof portfolioSold out1.8% → —
- Maze Therapeutics−1.5 ppof portfolioSold out1.7% → —
- Nuvalent+11%more sharesIncreased11.1% → 13.7%
- Tango Therapeutics+59%more sharesIncreased1.7% → 3.7%
- Viridian Therapeutics+114%more sharesIncreased1.3% → 2.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Revolution MedicinesRVMD22.3%
- Nuvalent13.7%
- Edgewise TherapeuticsEWTX7.8%
- Genmab A/SGMAB6.8%
- Spyre TherapeuticsSYRE6.4%
- Apogee Therapeutics3.9%
- Oruka TherapeuticsORKA3.8%
- Tango TherapeuticsTNGX3.7%
- Belite BioBLTE3.6%
- ErascaERAS3.3%
- Tarsus PharmaceuticalsTARS3.3%
- Alnylam PharmaceuticalsALNY2.7%
- InsmedINSM2.6%
- MBX BiosciencesMBX2.6%
- VaxcytePCVX2.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 28
Q2 2026: 75%
Q2 2026: 18.3%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Aug 27, 2026 (high confidence).
The data, as reported: PARADIGM BIOCAPITAL ADVISORS LP (CRD 312544): 7.B private funds: 2 hedge (gross assets $4.1 bn); 5.D assets by client type: pooled vehicles 90%, other 10% (of $4.5 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Baupost GroupInvestment firm · $5.4 bn
- Resolution CapitalInvestment firm · $5.4 bn
- Abrams Capital ManagementInvestment firm · $5.5 bn
- Skye Global ManagementInvestment firm · $5.1 bn
- Veritas Asset Management LLPInvestment firm · $5.6 bn
- Akre Capital ManagementInvestment firm · $5.1 bn